Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q4G176

UPID:
ACSF3_HUMAN

ALTERNATIVE NAMES:
Acyl-CoA synthetase family member 3

ALTERNATIVE UPACC:
Q4G176; A8K4J8; C9JQL6; Q6INA0; Q8N2F7

BACKGROUND:
The mitochondrial enzyme Malonate--CoA ligase ACSF3, alternatively known as Acyl-CoA synthetase family member 3, is essential for initiating intramitochondrial fatty acid synthesis. It specifically activates malonate and methylmalonate, crucial for energy production and lipid formation, with a preference for longer-chain fatty acids.

THERAPEUTIC SIGNIFICANCE:
Malonate--CoA ligase ACSF3 is implicated in Combined malonic and methylmalonic aciduria, a disease marked by severe metabolic imbalance, leading to various neurological and developmental complications. Targeting the function of Malonate--CoA ligase ACSF3 offers a promising avenue for developing treatments for this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.